Image
26.04.2024
Research highlights from our Professional Conference 2024
Our Professional Conference wrapped up last week after three days, 101 hours of diabetes science and lear...
customer support
customer support
From research findings supporting SGLT-2 inhibitors as a first-choice type 2 treatment to a real-world study strengthening evidence for teplizumab in early type 1, here are some of the diabetes research developments announced in February 2026.
Read more